Hla-mismatched Transplantation
Hla-mismatched Transplantation - Related Videos
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
0 Views •
Cited by 2 •
2017
Mismatches in human leukocyte antigen (HLA) sequences between organ donor and recipient pairs are the major cause of antibody-mediated rejection in organ transplantation. Here we present the use of custom antigen arrays that are based on individual donors' HLA sequences to probe anti-donor HLA alloantibodies in organ recipients.
03:15
A Peptide Array-Based Detection of Anti-donor HLA Alloantibodies in Organ Recipients
0 Views •
2025
This video demonstrates an assay to detect anti-donor HLA alloantibodies in organ recipients. A peptide array is synthesized to represent potential epitopes for antibody-mediated organ rejection. The array is incubated with the recipient's serum, containing alloantibodies that bind to their target epitopes. Antibody binding is detected using chemiluminescence to identify donor-specific HLA epitopes that incite alloantibody reactivity.
01:48
Mismatch Repair
0 Views •
2020
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.The Mutator Protein Family Plays a Key Role in DNA Mismatch RepairThe human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:20
Mismatch Repair
0 Views •
2023
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes. The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
07:59
Murine Full-thickness Skin Transplantation
0 Views •
Cited by 41 •
2017
Murine full-thickness skin transplantation is a well-established model to study rejection in an alloimmune setting. Here, we provide a tutorial of each step involved in performing a BALB/c-->C57BL/6 full-thickness skin transplant.
FAQs
The central mechanism is immune recognition of HLA differences as signals of nonself. Recipient T cells may respond to donor cells, producing an immune attack associated with graft rejection. In hematopoietic transplantation, donor immune cells can instead recognize recipient tissues, creating the basis for graft-versus-host disease. These opposing directions explain why the same mismatch can create different clinical risks.
The outcome depends on which immune system mounts the response. Recipient immune cells attacking the graft can damage donor tissue and promote rejection. Conversely, immune cells carried with a donor graft can attack recipient tissues, producing graft-versus-host disease. This distinction is especially important when evaluating hematopoietic stem-cell grafts compared with organ transplantation.
HLA typing identifies differences between donor and recipient at relevant HLA loci, giving clinicians information for donor selection. Choosing a donor with greater compatibility can reduce the degree of immune disparity that must be managed. When a fully matched donor is unavailable, this assessment helps balance access to transplantation against the increased possibility of rejection or graft-versus-host disease.
A fully matched donor generally presents fewer HLA differences for the immune system to recognize, whereas a mismatched graft carries greater potential for immune activation. The mismatched approach therefore requires careful risk reduction while offering an important alternative when no fully matched donor can be found. Its value is increased access, despite more complex immune management.
Management begins with HLA typing of donor and recipient, followed by donor selection based on the available compatibility information. Clinicians then use conditioning and immunosuppressive therapy to reduce harmful immune responses around transplantation. Together, these measures address both the initial immune disparity and the subsequent risk of graft rejection or graft-versus-host disease.
Clinicians may consider this approach when a fully matched donor is unavailable but transplantation remains important for the patient. It can expand access to hematopoietic stem-cell and organ grafts for people with cancers, immune disorders, or organ failure. The decision reflects a need to provide a graft while managing the additional immune risks created by HLA differences.
This topic provides a direct model for studying how immune systems distinguish self from nonself and how T-cell responses shape transplant outcomes. Research on these reactions supports safer donor-selection, conditioning, and immunosuppressive strategies. It also connects basic immunology with clinical efforts to improve transplantation for cancers, immune disorders, and organ failure.